Phreesia, Inc. (NYSE:PHR) Shares Sold by Champlain Investment Partners LLC

Champlain Investment Partners LLC lessened its position in Phreesia, Inc. (NYSE:PHR - Free Report) by 1.9% during the 4th quarter, according to the company in its most recent disclosure with the Securities and Exchange Commission (SEC). The institutional investor owned 2,456,149 shares of the company's stock after selling 47,688 shares during the quarter. Champlain Investment Partners LLC owned about 4.23% of Phreesia worth $61,797,000 as of its most recent SEC filing.

Several other hedge funds and other institutional investors have also made changes to their positions in the company. Marshall Wace LLP raised its stake in Phreesia by 416.9% in the 4th quarter. Marshall Wace LLP now owns 95,085 shares of the company's stock valued at $2,392,000 after purchasing an additional 76,690 shares during the last quarter. Zacks Investment Management boosted its position in Phreesia by 67.5% during the fourth quarter. Zacks Investment Management now owns 46,411 shares of the company's stock worth $1,168,000 after acquiring an additional 18,710 shares during the last quarter. NewEdge Advisors LLC grew its stake in Phreesia by 12.1% during the 4th quarter. NewEdge Advisors LLC now owns 4,256 shares of the company's stock valued at $107,000 after acquiring an additional 459 shares in the last quarter. XTX Topco Ltd raised its holdings in Phreesia by 76.4% in the 4th quarter. XTX Topco Ltd now owns 19,134 shares of the company's stock valued at $481,000 after acquiring an additional 8,290 shares during the last quarter. Finally, Barclays PLC raised its holdings in Phreesia by 120.4% in the 4th quarter. Barclays PLC now owns 209,209 shares of the company's stock valued at $5,264,000 after acquiring an additional 114,280 shares during the last quarter. Hedge funds and other institutional investors own 92.10% of the company's stock.

Phreesia Trading Up 1.0 %

Shares of PHR stock traded up $0.23 during trading hours on Tuesday, hitting $23.48. The company had a trading volume of 144,450 shares, compared to its average volume of 432,794. The company has a debt-to-equity ratio of 0.04, a current ratio of 1.74 and a quick ratio of 1.74. The company's fifty day moving average is $25.97 and its 200 day moving average is $24.33. Phreesia, Inc. has a fifty-two week low of $17.07 and a fifty-two week high of $30.53. The stock has a market capitalization of $1.38 billion, a PE ratio of -15.99 and a beta of 0.82.

Insider Activity at Phreesia

In other news, CFO Balaji Gandhi sold 28,759 shares of the firm's stock in a transaction that occurred on Thursday, February 13th. The shares were sold at an average price of $30.00, for a total value of $862,770.00. Following the completion of the transaction, the chief financial officer now owns 116,174 shares of the company's stock, valued at approximately $3,485,220. This trade represents a 19.84 % decrease in their ownership of the stock. The transaction was disclosed in a document filed with the SEC, which can be accessed through the SEC website. Also, General Counsel Allison C. Hoffman sold 6,556 shares of the company's stock in a transaction that occurred on Monday, January 27th. The stock was sold at an average price of $27.48, for a total transaction of $180,158.88. Following the sale, the general counsel now directly owns 152,361 shares in the company, valued at approximately $4,186,880.28. The trade was a 4.13 % decrease in their ownership of the stock. The disclosure for this sale can be found here. In the last 90 days, insiders have sold 145,804 shares of company stock worth $4,041,789. 5.80% of the stock is currently owned by company insiders.

Wall Street Analysts Forecast Growth

PHR has been the subject of a number of analyst reports. KeyCorp dropped their price target on Phreesia from $30.00 to $28.00 and set an "overweight" rating for the company in a research report on Wednesday, April 16th. Royal Bank of Canada upgraded Phreesia from a "sector perform" rating to an "outperform" rating and upped their target price for the company from $24.00 to $32.00 in a report on Wednesday, January 8th. Piper Sandler reiterated an "overweight" rating and set a $33.00 price target (up previously from $31.00) on shares of Phreesia in a report on Wednesday, January 29th. DA Davidson dropped their price objective on shares of Phreesia from $36.00 to $34.00 and set a "buy" rating for the company in a report on Monday, April 14th. Finally, Needham & Company LLC restated a "buy" rating and set a $29.00 price objective on shares of Phreesia in a research report on Thursday, March 13th. Twelve research analysts have rated the stock with a buy rating, According to MarketBeat, the company presently has a consensus rating of "Buy" and a consensus target price of $31.33.

About Phreesia

Phreesia, Inc provides an integrated SaaS-based software and payment platform for the healthcare industry in the United States and Canada. The company offers access solutions that offers appointment scheduling system for online appointments, reminders, and referral tracking management; registration solution to automate patient self-registration; revenue cycle solution, which offer insurance-verification processes, point-of-sale payments applications, post-visit payment collection, and flexible payment options; and network connect solution to deliver clinically relevant content to patients.